Results for tag: "Vascular Endothelial Growth Factor B Drug"

The Vascular Endothelial Growth Factor B (VEGF-B) Drug market is a subset of the Cardiovascular Drugs market. VEGF-B Drugs are used to treat cardiovascular diseases such as coronary artery disease, congestive heart failure, and peripheral artery disease. These drugs work by stimulating the growth of new blood vessels, which can improve blood flow and reduce the risk of heart attack and stroke. VEGF-B Drugs are also used to treat other conditions such as diabetes, kidney disease, and cancer. VEGF-B Drugs are typically administered intravenously or subcutaneously. Common side effects include nausea, headache, and dizziness. The market for VEGF-B Drugs is expected to grow in the coming years due to the increasing prevalence of cardiovascular diseases and the need for more effective treatments. Some companies in the VEGF-B Drug market include Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Show Less Read more